Menveo 10 ug/.5mL
Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine · INJECTION, SOLUTION · GlaxoSmithKline Biologicals SA
Menveo is a injection, solution containing meningococcal (groups a, c, y and w-135) oligosaccharide diphtheria crm197 conjugate vaccine at 10 ug/.5mL, taken intramuscular. Manufactured by GlaxoSmithKline Biologicals SA.
Key Facts
- Brand Name
- Menveo
- Generic Name
- Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
- NDC Code (Product)
58160-827- Manufacturer
- GlaxoSmithKline Biologicals SA
- Strength
- 10 ug/.5mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAMUSCULAR
- Marketing Status
- Application #
- BLA125300
- Marketing Start
- 12/09/2022
Recall History
No Recall HistoryFrequently Asked Questions
What is Menveo used for?
Menveo contains Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine. It is a injection, solution taken intramuscular. Consult your doctor for specific uses.
Is Menveo a controlled substance?
Menveo is not classified as a controlled substance by the DEA.
What is the generic name for Menveo?
The generic name for Menveo is Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine. There are no other listed brand versions of Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine.
What is the NDC code for Menveo 10 ug/.5mL?
The NDC (National Drug Code) for Menveo 10 ug/.5mL is 58160-827, listed by GlaxoSmithKline Biologicals SA.
Other Menveo Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)